|Articles|June 1, 2003

TIM's: Trying to Draw Comparisons

San Francisco -- Results of a study evaluating topical tacrolimus ointment 0.03 percent (Protopic) indicate it is a safe and effective treatment for patients of all ages with mild to moderate atopic dermatitis (AD), John Y M Koo, M.D., said at the annual meeting of the American Academy of Dermatology.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!

Related Content

Arcutis Completes Enrollment in Phase 2 Study of Roflumilast Cream for Infant AD

ByMarie Bosslett, Assistant Editor

November 13th 2025

Yasmine Kirkorian, MD, Discusses Genetic Clues and Advances in Pediatric Dermatology

ByMarie Bosslett, Assistant Editor,Yasmine Kirkorian, MD

November 6th 2025

Roflumilast Cream 0.05% Now Commercially Available for Pediatric Atopic Dermatitis

ByMarie Bosslett, Assistant Editor

October 30th 2025

Lisa Swanson, MD, On Emerging Pediatric Psoriasis Therapies

ByLisa Swanson, MD, FAAD,Maddi Hebebrand, MC, Associate Editor

October 29th 2025

Guselkumab Improves Quality of Life in Pediatric Patients With Psoriasis and Their Caregivers

ByVimal Prajapati, MD, FRCPC, DABD,Kaitlyn Bader, Assistant Managing Editor

October 17th 2025

Latest CME

Video

‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis

Raj Chovatiya, MD, PhD, MSCI, FAAD; Michael Rubio, PA-C, MMSc

Video

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Joseph Gorelick, MSN, FNP-C

Video

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Multimedia

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Register now!

Video

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Video

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Video

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Video

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Video

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Video

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Multimedia

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Video

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

TIM's: Trying to Draw Comparisons

Newsletter

Related Content

Arcutis Completes Enrollment in Phase 2 Study of Roflumilast Cream for Infant AD

Yasmine Kirkorian, MD, Discusses Genetic Clues and Advances in Pediatric Dermatology

Roflumilast Cream 0.05% Now Commercially Available for Pediatric Atopic Dermatitis

Lisa Swanson, MD, On Emerging Pediatric Psoriasis Therapies

Guselkumab Improves Quality of Life in Pediatric Patients With Psoriasis and Their Caregivers

Latest CME

‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Trending on Dermatology Times

Dupilumab Demonstrates Positive Effects on TCS Use, Growth in Pediatric Patients

Topical and Systemic Tools Expand Options for Hair Loss, Pigmentary Disorders, and Hand Eczema

Pilot Study Tests Oral NAC as Adjunct in Vitiligo Therapy

Day 1 Recap: Elevate-Derm Fall Conference

Arcutis Completes Enrollment in Phase 2 Study of Roflumilast Cream for Infant AD